Dr GAVOILLE Céline

Fiche personne

Coordonnées

Institut de Cancérologie de Lorraine
6 avenue de Bourgogne
54511 VANDOEUVRE-LES-NANCY Cedex

03 83 59 84 61

Territoire

Lorraine

Statut

Hospitalier

Affiliation

Institut de cancérologie de Lorraine (ICL)

Équipes/plateformes

Oncologie médicale

Recherche

Expertises :
- Clinique:Oncologie Médicale

Projets

Etude des biomarqueurs solubles de l'angiogenèse chez les patients atteints de cancer du rein métastatiques traités par everolimus (BIOSOLAER)

2012 - Porteur du projet : Dr GAVOILLE Céline

Publications

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Kim D, Chung H, Abed M, Ma J, Molden N, Shim C, Rajendran D, Yen J, Jeong J, Levy A, Yaniz-Galende E, Blanc-Durand F, Desauw C, Follana P, Bonichon-Lamichhane N, Oudard S, D'Hondt V, Gavoille C, Jandial DD, Meric-Bernstam F, Liu JF, Simpkins F, Randall LM, Leary A, Lackner MR, Harismendy O

NPJ Precis Oncol. 2026 05 30;:

Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study.

Harlé A, Gavoille C, Bouché O, Abdelghani MB, Plaza J, Spaeth D, Boudrant A, Ghiringhelli F, Villing AL, Borg C, Rouyer M, Husson M, Gilson P, Salleron J, Lambert A, Merlin JL

Oncol Lett. 2026 01;31(1):13

Impact of Electronic Transition and Prefilled Templates on Drug Prescription Compliance: Retrospective Study.

Lambert A, Hombourger B, Salleron J, Chergui F, Vallance C, Nicolas N, Moussouni M, Cherif L, Chenot E, Gavoille C, Massard V

J Med Internet Res. 2025 04 9;27:e57782

Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.

Bourien H, Lefevre LB, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Gavoille L, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Tixidre CG, Coeffic D, Morvan A, Collard O, DE LA Motte Rouge T

Anticancer Res. 2023 02;43(2):653-662

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.

Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, Frenel JS, Abadie-Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Brachet PE, Giffard F, Weiswald LB, Just PA, Blanc-Fournier C, Leconte A, Clarisse B, Leary A, Poulain L

Gynecol Oncol. 2022 Feb 2;:

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer.

Thierry AR, Pastor B, Pisareva E, Ghiringhelli F, Bouché O, De La Fouchardière C, Vanbockstael J, Smith D, François E, Dos Santos M, Botsen D, Ellis S, Fonck M, André T, Guardiola E, Khemissa F, Linot B, Martin-Babau J, Rinaldi Y, Assenat E, Clavel L, Dominguez S, Gavoille C, Sefrioui D, Pezzella V, Mollevi C, Ychou M, Mazard T

JAMA Netw Open. 2021 Sep 1;4(9):e2124483

Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review.

Lambert A, Salleron J, Kieffer A, Raymond P, Geoffrois L, Gavoille C

Bull Cancer. 2020 Jun 5;:

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.

Franczak C, Witz A, Geoffroy K, Demange J, Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P, Gambier N, Scala-Bertola J, Merlin JL, Harlé A

PLoS ONE. 2020 ;15(1):e0227294

Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC).

Brachet PE, Joly Lobbedez F, Fabbro M, Leary A, Medioni J, Follana P, Lesoin AF, Frenel JS, Abadie Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Just PA, Blanc-Fournier C, Giffard F, Clarisse B, Poulain L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii347

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis.

Mazard T, Ghiringhelli F, Mollevi C, Assenat E, Gavoille C, Smith D, Pezzella V, Meddeb R, Pastor B, Ychou M, Thierry AR

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii204

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.

Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, Le Tourneau C

JCO Precis Oncol. 2018 ;2:

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M

Ann. Oncol.. 2017 Sep;28(9):2149-2159

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.

Lambert A, Gavoille C, Conroy T

Therap Adv Gastroenterol. 2017 Aug;10(8):631-645

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial.

Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C

Ann. Oncol.. 2016 Dec;:

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Tourneau CL, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X

Lancet Oncol. 2015 Sep 2. pii: S1470-2045(15)00188-6

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Le Tourneau C, Paoletti X, Servant N, Bieche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Tredan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M

Br J Cancer. 2014 Jul 8;111(1):17-24